Medx - heute kommen wir wieder über 60$ - 500 Beiträge pro Seite

[neversaynever]

wenn die Nasdaq halbwegs stabil bleibt.

[NfDrag]

und selbst wenn nicht

[D 55]

Aktuell bei 56,75 um 18.30 Uhr!

[patera]

Ich halte mein Kurziel bis ende nächster Woche aufrecht,
was meint ihr. 100 Euro

[marvy30]

Leute,habt doch mal ein wenig Geduld,Medarex wird noch groß kommen*freu*

[patera]

Geduld ist immer gut,
aber 100 Euro sehen wir trotzdem nächste
Woche,sind denn nicht die Biotech konferenzen
nächste Woche

[neversaynever]

wenn ich Geduld hätte, würd ich cisco oder lernout&hauspie speech kaufen und 3 Jahre drauf sitzen bleiben aber nicht medx.

[volkswagen]

Raven Biotechnologies Builds Senior Management Team With the Addition Of Two Key Biotech Executives

SAN CARLOS, Calif., May 4, 2000 /PRNewswire via COMTEX/ -- Raven
Biotechnologies, Inc. today announced the appointment of two senior executives
to its management team. Gordon A. Vehar, Ph.D. has joined as Vice President,
Research and Development, and Donald W. Perryman has assumed the
responsibilities of Vice President and Chief Business Officer. Both will report
to Jennie P. Mather, Ph. D., founder, President and CEO of Raven.

"We are very excited about the addition of two such highly qualified and
experienced people to our management team," said Dr. Mather. "With Gordon and
Don, we now have the depth in product development and business experience to
move rapidly into the next stage of growth."

Dr. Vehar was most recently at Genentech, where he held a variety of positions
within the company in his 20 years there. In addition to conducting his own
research team, he has significant experience managing project teams from the
research/discovery stage through to product development, having been Project
Team Leader on six research projects that went on to development, including
cancer, cardiovascular and immunologic agents. He also served as Director of the
Cardiovascular Research Department for three years. His most recent research at
Genentech was in the area of protein microsequencing applications directed
towards antigen identification for selected monoclonal antibodies. Dr. Vehar is
co-inventor on 33 issued patents, has authored more than 35 publications and is
the only individual in the 28-year history of the Intellectual Property Owners
Association to have twice received Inventor of the Year Awards. Dr. Vehar
received his Ph. D. from the University of Cincinnati Medical School and did his
postdoctoral work with Dr. Earl Davie at the University of Washington, Seattle.

Mr. Perryman comes to Raven with 26 years experience in sales, marketing,
business development and general management in start-up as well as established
company environments. Most recently, he was with Rigel Pharmaceuticals, Inc., a
biotechnology start-up, where he was Vice President of Business Development from
its inception until filing its initial public offering. At Rigel he led the
effort that resulted in five commercial research collaborations and numerous
technology access deals. Prior to that, he was Vice President of Marketing,
Worldwide for the Pharmaceutical Division, for Centocor. He was responsible
there -- as well as in previous positions -- for cardiovascular, immunology,
oncology and pulmonary products, marketed both through partners and directly.
His biotech, pharmaceutical and diagnostics experience includes broad
international responsibilities, including an assignment as European General
Manager and experience in Japan and Latin America. Mr. Perryman earned his
Bachelor of Arts and MBA from the University of Illinois.

Founded in 1999, Raven is a privately held biotechnology company focused on the
rapid discovery of functionally validated drug targets on the cell surface and
the development of monoclonal antibodies or other therapeutics to regulate them.
This approach integrates three key technologies that enable Raven to rapidly
select novel, high quality targets for drug development that are functionally
validated at each step. First, the company has a unique expertise in culturing
cells in a manner that allows them to create organ and disease-specific,
phenotypically stable human cell lines from cell types not previously grown in
the laboratory, and maintain their ability to function as they do in the body.
Secondly, using these proprietary cell lines, Raven can rapidly generate a panel
of active monoclonal antibodies that bind to cell surface proteins. Finally,
using proteomic and genomic approaches, the Company has developed methods to
rapidly identify these proteins and "map" the surface of the cell, giving a more
complete functional context for the target`s activity as well as providing
alternative candidate targets. Raven is initially directing its technology
toward the discovery of monoclonal antibody therapeutics for cancer, endocrine
and neurological diseases and has signed one partnership with Medarex for the
discovery and development of cancer therapeutics. For more information on Raven
Biotechnologies, please visit the Company`s web site at www.ravenbio.com.

SOURCE Raven Biotechnologies, Inc.

[marvy30]

wär ja echt high wenn die nächste woche bei 100 stehen,ich glaub dann verkauf sogar ich ;-))

[neversaynever]

nächste Woche 100$, so so ...
also entweder stehen die bei über 300$, weil sie ein Medikament zugelassen bekommen haben, was bis nächste Woche zugegebenermaßen mehr als unwahrscheinlich ist, oder sie sind irgendwo zwischen 35$ und 80$, aber bei 100$ totsicher nicht.

[patera]

Aber durch die Biotech Konferenzen halte ich 100 Euro
trotzdem für realistisch.
Die panikmache bei den Biotechs was doch alles
nur ein "Scheiß" spiel von Fonds die die Rally
verschlafen haben

[neversaynever]

wenn der Euro weiter so fällt, sind 100€ in der Tat nicht unmöglich ...

[luke49]

Glaube ich auch nicht, aber realistischer finde ich 80-90€.
mfg

[zarkar]

Hallo zusammen,

weiss jemand genauer wann die Quartalszahlen kommen, und wie die
Tendenz ist.
Bin am überlegen, ob ich morgen nicht doch lieber Kasse mache.

Gruss
Zarkar

[MR. Montana]

hi zusammen,

zarkar - willst du traden oder was? wie kann man denn aus medarex ernsthaft rausgehen wollen??!!

überleg´s dir gut...

mfg,

Mr. Montana

[R.O.]

Hallo zusammen.
Keiner mir einer was zu den Biotech
Konferenzen nächster Wocher sagen.
Worüber da geredet wird usw.
Besten Dank